Vantage logo

Biotech catalysts on the horizon

The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.

Vantage logo

Amylyx faces an uphill battle

Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?